Lykan BioScience, LLC

Lykan BioScience, LLC develops advanced biotechnological solutions focused on enhancing gene therapies and cellular treatments, providing innovative tools for gene and cell delivery to improve therapeutic efficacy and safety. Lykan BioScience, LLC specializes in providing biotechnological solutions aimed at improving gene therapies and cellular treatments. The company is headquartered in Phoenix, US. The CEO, Anthony Rotunno, leads the firm, which was recapitalized in June 2019 by WindRose Health Investors, although specific financial details of the deal were not disclosed.

The company has successfully completed 1 deal. Lykan Bio specializes in developing advanced biotechnological solutions designed to enhance gene therapies and cellular treatments. The core product offerings focus on innovative tools for cell and gene delivery systems, crucial for treating genetic disorders and advancing personalized medicine. Lykan Bio serves a diverse clientele, including pharmaceutical companies and research institutions across North America and Europe, enabling them to streamline their R&D processes and improve treatment outcomes in various disease areas, including genetic diseases and cancers.

Revenue generation at Lykan Bio is structured through strategic partnerships and direct sales to research and pharmaceutical companies. The firm engages primarily in B2B transactions, providing proprietary technologies and services to clients needing advanced gene delivery systems for therapeutic developments. Pricing plans are tailored to meet individual client needs, ensuring flexibility in deploying their flagship products, further supporting collaborations with research institutions for mutual advancement in biotechnology. Lykan Bio plans to innovate its product line with new tools aimed at enhancing gene delivery systems, though specific release dates are not provided.

The company is also looking to expand into additional markets, targeting regions in Europe by the end of 2023. The recapitalization in June 2019 is expected to support these growth initiatives, allowing Lykan Bio to enhance its technological offerings and market reach.